Emily Quinn speaks from the TED stage at TEDWomen 2018; Credit: /TED

Part 1 of the TED Radio Hour episode The Biology Of Sex

Artist Emily Quinn is intersex. She's one of over 150 million people in the world who don't fit neatly into the categories of male or female. She explains how biological sex exists on a spectrum.

About Emily Quinn

Emily Quinn is an artist and activist. She worked at Cartoon Network on the Emmy Award winning show, Adventure Time. While there she partnered with interACT and MTV to develop the first intersex main character in television history. She came out publicly as intersex in a PSA alongside the character's debut. She later worked as the Youth Coordinator for interACT: Advocates for Intersex Youth.

As an activist, she speaks about intersex issues before audiences and through her YouTube channel: intersexperiences. As an artist, her most recent projects include a genderless puberty guidebook and a portrait series of intersex people that will be exhibited at medical schools across the U.S. in 2020.

This content is from Southern California Public Radio. View the original story at SCPR.org.

No field trips. No game rooms. No teddy bears. These are some of the CDC's guidelines for reopening schools, childcare centers and day camps safely in places where coronavirus cases are on the decline.

The guidance, which also covers restaurants, churches and other public places, was obtained by The Associated Press, which reports that the White House tried to keep it from coming to light. The New York Times quoted Mark Meadows, the chief of staff, as being concerned that the guidelines were "overly prescriptive."

The CDC does not have authority to enforce its guidance, which is intended for public information only; the actual policy decisions are up to state and local governments. Schools are closed through the end of the school year throughout much of the country, with the exception of Montana, which welcomed a handful of students back this week. Child care protocols are different in different states.

But millions of parents need child care so they can work, and socialization and stimulation for children who have been confined to home by lockdowns for weeks on end. This is the guidance that summer camps and day cares have been waiting for to make decisions about reopening safely.

The guidance says that where coronavirus is spreading rapidly, child care should only serve the children of essential workers. This is the case today in much of the country, which the guidelines refer to as "Phase 1".

In Phase 2, programs can expand to serve all children with enhanced social distancing measures, and in Phase 3, with a lower risk, social distancing will continue.

Recommended measures include:

Handwashing;

Cloth masks for staff;

Regular disinfection of all surfaces;

Six-foot distance "if possible," head-to-toe positioning with bedding;

As much outdoor air as possible — open windows, fans;

Restricting mixing of groups;

Restricting visitors, and staggering dropoffs and pickups to reduce contact among parents;

Limiting sharing of materials like art supplies or toys. Disinfecting them in between use.;

Avoiding soft toys that can't be easily disinfected;

Not using common areas like dining halls or playgrounds if possible. If it is necessary, stagger visits and disinfect in between;

Adjust operations based on local health data;

Monitor absenteeism.

The guidelines also emphasize keeping attendance at such programs local, to limit children bringing the disease from high to low transmission areas.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Emily Quinn speaks from the TED stage at TEDWomen 2018; Credit: /TED

Part 1 of the TED Radio Hour episode The Biology Of Sex

Artist Emily Quinn is intersex. She's one of over 150 million people in the world who don't fit neatly into the categories of male or female. She explains how biological sex exists on a spectrum.

About Emily Quinn

Emily Quinn is an artist and activist. She worked at Cartoon Network on the Emmy Award winning show, Adventure Time. While there she partnered with interACT and MTV to develop the first intersex main character in television history. She came out publicly as intersex in a PSA alongside the character's debut. She later worked as the Youth Coordinator for interACT: Advocates for Intersex Youth.

As an activist, she speaks about intersex issues before audiences and through her YouTube channel: intersexperiences. As an artist, her most recent projects include a genderless puberty guidebook and a portrait series of intersex people that will be exhibited at medical schools across the U.S. in 2020.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Full Text:

The molecular mechanism used by many bacteria to kill neighboring cells has redundancy built into its genetic makeup, which could allow for the mechanism to be expressed in different environments, say researchers at Penn State and the University of Wisconsin-Madison. Their new study provides insights into the molecular mechanisms of competition among bacteria. "Many organisms, including humans, acquire bacteria from their environment," said Tim Miyashiro, a biochemist and molecular biologist at Penn State and the leader of the research team. "These bacteria can contribute to functions within the host organism, like how our gut bacteria help us digest food. We're interested in the interactions among bacteria cells, and between bacteria and their hosts, to better understand these mutually beneficial symbiotic relationships." Cells of the bioluminescent bacteria Vibrio fisheri take up residence in the light organ of newly hatched bobtail squid. At night, the bacteria produce a blue glow that researchers believe obscures a squid's silhouette and helps protect it from predators. The light organ has pockets, or crypts, in the squid's skin that provide nutrients and a safe environment for the bacteria. "When the squid hatches, it doesn't yet have any bacteria in its light organ," said Miyashiro. "But bacteria in the environment quickly colonize the squid's light organ." Some of these different bacteria strains can coexist, but others can't. "Microbial symbioses are essentially universal in animals, and are crucial to the health and development of both partners," says Irwin Forseth, a program director in the National Science Foundation's Division of Integrative Organismal Systems, which funded the research. "The results from this study highlight the role small genetic changes can play in microbe interactions. Increased understanding will allow us to better predict organisms' performance in changing environments."

Image credit: Andrew Cecere

Full Text:

A new study shows that graphene sheets can block the signals mosquitoes use to identify a blood meal, potentially enabling a new chemical-free approach to mosquito bite prevention. Researchers showed that multilayer graphene can provide a twofold defense against mosquito bites. The ultra-thin yet strong material acts as a barrier that mosquitoes are unable to bite through. At the same time, experiments showed that graphene also blocks chemical signals mosquitoes use to sense that a blood meal is near, blunting their urge to bite in the first place. The findings suggest that clothing with a graphene lining could be an effective mosquito barrier.

Image credit: Hurt Lab/Brown University

US-based fintech Namogoo will integrate incentive platform

Source: Streetwise Reports   04/23/2020

Global healthcare packaging components manufacturer company West Pharmaceutical Services Inc. (WST:NYSE) today announced financial results for its first quarter ending March 31, 2020 and provided updated full-year 2020 financial guidance.

The company reported that net sales in Q1/20 increased to $491.5 million, a 10.8% increase from $443.5 million in Q1/19. During the same corresponding period, the firm stated that non-GAAP diluted earnings per share (EPS) increased by 36% to $0.99 and non-GAAP adjusted-diluted EPS increased by 36% to $1.01.

West Pharmaceutical Services advised that it is maintaining its FY/20 net sales guidance, which is expected to be in a range of $1.95-1.97 billion. The company stated that it is updating FY/20 adjusted-diluted EPS guidance to a new range of $3.52-3.62, compared to the prior estimated range of $3.45-3.55.

The company's President and CEO Eric M. Green commented, "During these unprecedented times, our priorities are focused on the well-being and safety of our team members as well as ensuring the supply of critical, high-quality components and solutions to our customers...I am extremely pleased that we delivered a strong performance in the first quarter given the challenging environment that the COVID-19 pandemic has had on our customers, our suppliers and our team members. In particular, we continued to deliver strong sales growth in high-value products, as demand trends from our worldwide customer base were similar to trends we saw last year. Our teams are partnering with a broad range of customers working to support efforts to develop solutions that address the global COVID-19 pandemic such as diagnostics, anti-viral therapeutics and vaccines."

The firm outlined sales in the most recent quarter by product line. The company reported that in Q1/20, net sales in its Proprietary Products segment grew by 9.7% to $373.5 million and that this segment "saw good demand for Westar^®, Daikyo^®, NovaPure^® and FluroTec^® components as well as for devices such as Daikyo Crystal Zenith^® syringes and cartridges and our self-injection platforms."

The firm noted that net sales from its Contract-Manufactured Products segment grew by 14.5% to $118.1 million led by sales of components for diagnostic devices and drug-injection delivery devices.

The company added that the Biologics market unit enjoyed double-digit organic sales growth, the Generics market unit achieved high-single digit organic sales growth and the Pharma market unit registered mid-single digit organic sales growth.

The firm additionally noted that during Q1/20 under its share repurchase program, it repurchased 761,500 shares for $115.5 million at an average share price of $151.65.

West Pharmaceutical Services is headquartered in Exton, Pa., roughly 35 miles west of Philadelphia, and is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems.

West Pharmaceutical has market capitalization of around $13.5 billion with approximately 73.84 million shares outstanding. WST shares opened 5.25% higher today at $179.05 (+$8.93, +5.25%) over yesterday's $170.12 closing price and reached a new 52-week high price this morning of $190.27. The stock has traded today between $177.13 and $190.27 per share and is currently trading at $187.04 (+$17.17, +10.11%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: WST:NYSE, )

Source: Streetwise Reports   05/06/2020

Testing has been an Achilles heel of the coronavirus pandemic, but ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB) has partnered with Dr. Hans Frykman and the BC Neuroimmunology Lab to use its unique technology to create a more accurate antibody test for SARS-CoV-2, the virus that causes Covid-19.

Two main types of tests exist for Covid-19: one that detects the presence of the virus that causes Covid-19, which indicates a person has an active infection, and another that detects antibodies, showing that a person has been exposed to the virus.

The first test that was developed, a test for the presence of the virus, is used mainly to confirm diagnosis of Covid-19 in people who are showing symptoms such as a fever, a dry, persistent cough, difficulty breathing, a sense of restriction in the chest. "They are typical signs of Covid-19, but we would want to know if these are signs of the common flu or a bad cold or Covid-19. We know that Covid can progress really significantly very quickly, especially in individuals with underlying conditions," ProMIS CEO Dr. Elliot Goldstein told Streetwise Reports. "The number of tests is limited, but it's not actually the tests themselves but the reagents and systems you need to run the test that are in short supply."

"Anytime you conduct a test for the virus and get a negative response, the test indicates only that on that day at that time, the person does not have the virus. The person could have had Covid and recovered, or might have had an asymptomatic or very mild case. Or that person could get the virus tomorrow or in three days," Dr. Goldstein explained. "At any point in time the virus test helps indicate the prevalence of the virus—how many people are actually infected—if you test broadly, and at the time you do it, you can determine whether an individual is currently infected or not."

The second type of test, called serological tests or assays, is also known as an antibody test. "When a person is recovering from a viral infection, the immune system makes antibodies—also called immunoglobulins—that are specific to the virus. They neutralize the virus and help clear it out; that's part of the mechanism of why you get better," Dr. Goldstein explained.

One way to see if a person has had Covid is to test for antibodies. "A positive test means you've been exposed to the virus because, in the absence of a vaccine, that's the only way you would have the antibodies. While it's not 100% certain that antibodies neutralize the virus, based on experience with other coronaviruses, it is likely," Dr. Goldstein said. Having the virus neutralized should offer at least some protection against future re-infections.

People who have had positive virus tests know that they have Covid or had Covid and recovered, but many people are asymptomatic or may have had what felt like a light cold, and they want to know if they are at risk, or if they have some protection against the disease. "This is really important for frontline healthcare workers, people working 8-10 hours a day in intensive care or the emergency room with patients known to be very sick with Covid-19; even with protective equipment, they have significant exposure to the virus," Dr. Goldstein explained. "If someone has been through the disease and has natural antibodies, they can't infect someone else. What you want to know on an individual level is am I safe from infection and am I safe for other people."

Generally, antibody testing is a fairly common procedure, Dr. Goldstein explained. When you spin blood in a centrifuge, it separates into three parts: red blood cells, plasma and serum. Serum is where you find antibodies. "ELISA (enzyme-linked immunosorbent assay) is a standard test that looks for antibodies, but it is not specific enough for the Covid-19 virus."

The challenge is there are multiple coronaviruses. "Four different coronaviruses are responsible for the common cold, and then there are others like SARS and MERS. They all have the same sort of halo or corona of protein around the outside of it," Dr. Goldstein said. "They look like the old naval mines used in war. The whole family of coronaviruses look like that. The amino acid sequences of different coronaviruses are not identical but very similar; they share a lot of common structures. There are only really small differences and you can't really pick them up using the usual physical methods."

Studies have shown that up to 90% of individuals in Western countries have been exposed to one or more of the common cold coronaviruses and have antibodies against them. "They look very similar to the coronavirus causing Covid-19. So in Covid-19 antibody tests, the most important thing is it has to be highly specific for the Covid-19 antibodies and doesn't test positive when it identifies a common cold antibody. That is a false positive," said Dr. Goldstein. "It's actually much safer not to have a test that has a lot of false positives because you could base a behavioral decision on faulty information."

Dr. Goldstein cited an example. "If you are testing 1,000 people and there is a 90% prevalence for the cold virus, that means around 900 people have antibodies to the common cold. If the prevalence of the Covid-19 virus is 2%, roughly 20 of the 1,000 would have antibodies to the Covid-19 virus. Let's say the serology test has 95% specificity. That means five times out of 100, it will give a false positive, indicating the presence of Covid-19 antibodies when it is really picking up antibodies against the cold virus. What this means is 5% of 900, or 45 people, will test positive for Covid when they have not had it, and are making decisions based on incorrect information. The consequences of being wrong are dramatic and highlight the need for a very good, high-quality serological test."

How does this relate to Alzheimer's and other neurological diseases that are ProMIS' core competency? "In Alzheimer's, ALS, frontotemporal dementia, Parkinson's disease and other neurological disease, we've been able to use our proprietary, unique technology to identify sites on misfolded proteins that are driving these diseases. Our core technology is the capability to understand what's special about the bad proteins that are causing these diseases and then we can make antibodies highly selective against them. Our technology allows us to identify a region, an epitopes target, which is a series of four to six amino acids where the protein has misfolded. Not only do we know where this target site is located, importantly we also determine the shape (conformation) of this site. Proteins like amyloid and alpha synuclein and TDP 43 misfold and when these proteins misfold they become toxic, they kill neurons, resulting in disease," Dr. Goldstein explained.

ProMIS has transferred that thinking to the virus causing Covid-19. "The corona is composed of the spiky protein. Remember, we want to be able to distinguish between the coronavirus causing the common cold and the coronavirus causing Covid-19," Dr. Goldstein said. "If we can distinguish between the two, we can have an antibody test that's specific for Covid-19. We are looking at a region of the virus called the receptor binding domain, the RBD, that is part of the spike protein and how it attaches to cells. We have a core competency that allows us to identify sites, and not just the location of the sites, but the shape of the sites on complex protein molecules. That allows us then to use that knowledge to create either antibodies or to create serum tests, or even quite frankly, we can use those targets to create vaccines."

Using ProMIS' proprietary technology, the company has been able to "identify a site that we believe is only present on the Covid-19 virus and not on other coronaviruses. We are now initiating the synthesis of several different forms of that site; it's a small area," Dr. Goldstein stated. "That would then transfer to Dr. Hans Frykman's lab at University of British Columbia, a world-class serology lab. Then we will see if the targets we've identified are specific and selective antibodies against Covid-19."

When you test the serum of an individual, if they've been exposed to the virus and have the antibodies, "those antibodies should bind selectively and specifically to the target. So if the antibodies from the patient's serum are binding to the target site, we know it's a Covid-19 virus because that site is only visible in that shape on the Covid-19 virus and not the others. For the validation of our test, only in patients known to have had Covid-19 should we see binding of antibodies against Covid-19 to our target. The second validation is based on testing in serum from subjects known to have never been exposed to Covid-19 virus—such subjects have antibodies only from cold or other coronaviruses, and therefore the antibody test should be negative; there should be no binding. So we should only see binding in serum from a patient known to have recovered from COVID-19, and we should not see binding in serum from an individual known not to have been exposed to COVID-19," Dr. Goldstein explained.

"Our technology basically allows us to zero in with sniper-like precision on the structure of a protein and understand it, not only the structure overall but the shape of the regions on that protein and then that allows us to identify what is specific to that protein, in this case the spiky protein on the virus causing COVID-19," said Dr. Goldstein.

ProMIS expects to have initial results in June.

Disclosure:
1) Patrice Fusillo compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: ProMIS Neurosciences. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of ProMIS, a company mentioned in this article.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: PMN:TSX; ARFXF:OTCQB, )

Source: Streetwise Reports   05/06/2020

Biopharmaceutical company Horizon Therapeutics Inc. (HZNP:NASDAQ), which focuses on developing and commercializing medicines for treatment of rare and rheumatic diseases, today announced its Q1/20 financial results for the period ending March 31, 2020. The firm began by advising that it is raising its FY/20 net sales guidance and revised its adjusted EBITDA guidance.

For Q1/20 the company reported that net sales increased by 27% to $355.9 million over Q1/19. The firm provided a breakdown of revenue by business unit and listed that in Q1/20 compared with Q1/19, its Orphan segment net sales increased 47% to $245.4 Million, KRYSTEXXA® net sales rose by 78% to $93.3 million and TEPEZZA (teprotumumab-trbw) net sales were $23.5 million, which exceeded expectations.

The firm advised that it is increasing FY/20 net sales guidance to $1.40-1.45 billion driven primarily by significantly higher TEPEZZA net sales and reflecting anticipated impacts from COVID-19. The company also presented revised FY/20 adjusted EBITDA guidance of $450-500 million, which reflects increased TEPEZZA program investment to support higher-than-expected demand.

The firm indicated that in Q1/20 it posted a GAAP net loss of $13.6 million with adjusted EBITDA of $107.2 million and non-GAAP net income of $83.2 million.

The company's Chairman, President and CEO Timothy Walbert commented, "We had a very strong start to 2020, highlighted by the early approval and rapid uptake of TEPEZZA, which significantly exceeded expectations, excellent KRYSTEXXA growth and our recent acquisition of HZN-825...We are increasing our full-year net sales guidance to account for significantly higher TEPEZZA net sales that more than offset the expected impact from COVID-19 this year, and we are widening both our net sales and adjusted EBITDA guidance ranges to account for future uncertainty. The fundamentals of our business are strong, including a robust cash position, and we continue to be very well positioned for the long term."

The company noted that it received FDA approval for TEPEZZA for the treatment of thyroid eye disease (TED) earlier this year in January. The firm described TED as "a rare, serious, progressive and vision-threatening autoimmune disease, and is associated with proptosis (eye bulging), diplopia (double vision), blurred vision, pain and facial disfigurement." The company further s explained that "TEPEZZA, a fully human monoclonal antibody insulin-like growth factor-1 receptor (IGF-1R) inhibitor, is the first and only FDA-approved medicine for the treatment of TED."

Horizon Therapeutics is a biopharmaceutical company headquartered in Dublin, Ireland. The firm researches, develops and commercializes medicines for treatment of rare and rheumatic diseases.

Horizon has a market capitalization of around $7.1 billion with approximately 190.2 million shares outstanding and a short interest of about 4.9%. HZNP shares opened 10% higher today at $44.19 (+$3.81, +10.19%) over yesterday's $37.38 closing price and reached a new 52-week high price this morning of $43.57. The stock has traded today between $40.00 and $43.90 per share and is currently trading at $42.95 (+$5.57, +14.90%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Levels of air pollution significantly increase on the island of Svalbard in the Norwegian Arctic when tourist cruise ships are present, according to a recent study. With shipping levels rising in the region, the researchers recommend that stricter emissions regulations are introduced in order to limit the impact of pollution on the Arctic environment.

Covering walls with plants can significantly reduce the temperature of building walls during hot summer months. A recent study of three different types of these ???living walls??? in Italy suggests that they can be 20??C cooler than a bare wall on sunny days. An added advantage is that living walls can be retrofitted to existing buildings.

A recent study has compared the environmental impact of a range of building materials. Energy consumption, carbon dioxide emissions and water demand can all be reduced by switching to renewable sources of energy, improving technologies and promoting eco-friendly alternative materials.

A method has been developed to compare how EU Member States have implemented the Energy Performance Buildings Directive. It suggests that implementation varies widely across Europe but that the Czech Republic, Finland, Portugal and Slovakia have kept to the Directive’s aims and guidelines most closely, based on data available in 2009.

The EU Joint Research Centre has produced a new part of the handbook that provides guidelines for developing and using Life Cycle Assessments (LCA), which evaluate the environmental impacts of products, focusing specifically on life cycle impact assessment (LCIA). It recommends that assessments should be comprehensive, accessible and easy to apply in order to make LCA a more mainstream concept in decision-making.

There is a wide range of systems for assessing and communicating the sustainability of buildings, but the variation can be confusing. Recent research has analysed the elements needed for effective assessment and examined the needs of stakeholders to inform the presentation and communication of assessment results.

Building Information Modelling (BIM) can enhance the design of a building, reduce costs and save energy. However, little research has been carried out on its impact on sustainable practices. A US survey illustrates that many practitioners do not see sustainability as a primary application, suggesting that more effort is needed to encourage the integration of ‘green’ design and construction into BIM.

Staff in buildings that have been certified as ‘green’ under the LEED scheme are just as satisfied with their indoor working environment as people working in non-LEED buildings, according to research on commercial buildings. The study suggests that investment in the thermal and acoustic aspects of buildings, however, would further improve occupant satisfaction.

Effective ‘knowledge exchange’ - the process of producing, sharing, understanding and using knowledge - is vital to good environmental management. New research has uncovered five principles for this process which could help researchers, decision makers and other parties work together to better manage environmental change.

The Grolier Codex, an ancient document that is among the rarest books in the world, has been regarded with skepticism since it was reportedly unearthed by looters from a cave in Chiapas, Mexico, in the 1960s.

read more

A set of guidelines has been developed to reduce soil erosion by planting vegetation in desertification hotspots.Farmers and policymakers can use the guidelines to identify the most suitable places to plant vegetation in the channels where water and sediment move through the landscape.

By analysing previous disasters, lessons learnt can be incorporated into policies and plans to manage the effects of future disasters. A recent study examining the 2009 L’Aquila earthquake in Italy suggests that although the national response effectively dealt with the emergency, longer-term measures to help local populations cope with the aftermath of the disaster need to be set out more clearly.

Where agricultural policies are in conflict with environmental and social issues, a 'roadmap' can provide a way forward as part of a sustainable rural development planning process. New research describes an approach used in the Netherlands, which brings together stakeholders to create a mutually desirable vision of the future.

Biochar is increasingly mixed into farm soils to improve crop productivity and maintain carbon stocks. However, it can change the way that pesticides applied to the same soil behave, according to a new study. The researchers suggest that farmers may also need to follow new guidelines on pesticide application if they add biochar to their soil.

The discomfort associated with hot, dry summers in some urban areas can be reduced by planting the most appropriate trees in open city spaces, according to a recent study. The researchers identified the Indian laurel fig as the most effective tree for this purpose in the Greek city of Chania.

The health risks to humans of using recycled water to irrigate crops needs to be carefully managed. New research has demonstrated that ???managed aquifer recharge??? can be just as effective as conventional water treatments in improving the quality of recycled water for use in irrigation.

In the aftermath of natural disasters, displaced communities require temporary accommodation. A new study has examined how the built environment of these temporary communities influences their recovery and resilience, using accommodation set up after Hurricane Katrina as a case study. It highlights the importance of developing transitional built environments that consider the social and mental health needs of a community.

A recent report has reviewed research on the effectiveness of low-noise road surfaces, taking into account acoustic performance, safety, skidding resistance and cost. It concludes they could have substantial acoustic and financial benefits, but their durability and safety must be taken into account.

A recent study presents a cost and time-effective way to identify areas with particularly low levels of noise pollution. The recommended method will make it easier for EU Member States to recognise quiet areas which could offer great health and ecological benefits, as well as meeting one of the Environmental Noise Directive requirements.

Living in a quiet area has a positive impact on health. A study compared quality of life for people living in quiet and noisy locations and found that those who lived in quiet locations—particularly in rural areas—had a better quality of life.

A recent study in Finland suggests new building regulations will lead to a substantial reduction in the total energy demand and CO2 emissions in new apartment buildings. This could have an impact on the source of energy used for new buildings. In particular, the demand for space heating will fall, which could have an impact on the source of energy used for new buildings.

Although the public are largely aware of climate change, their understanding of how they produce and manage carbon is generally not sufficient to lead to changes in behaviour and lifestyle, according to a recent study. The researchers therefore recommend policy action to increase the ‘carbon capability’ of the general public.

A new report on biofuels by the UK’s Nuffield Council on Bioethics has produced a set of five ethical principles to guide the development of biofuels technology and policy. It recommends applying these principles to create comprehensive standards to ensure that biofuels address, rather than exacerbate, global problems.

Long-term urban planning is needed to adapt the urban environment and make it more resilient to climate change, according to a new European Environment Agency (EEA) report that aims to support urban policy development and decision making.

A free online system for assessing the sustainability of buildings is due to be launched across Europe in July this year. The tool captures scientific complexity whilst being accessible and easy-to-use, its developers say.

Climate change is a particular threat to island nations and effective adaptation is vital. A new analysis examines current adaptation measures in tropical Oceania and identifies guidelines for implementing resilient, ecosystem-based adaptation (EbA). Among its recommendations, local communities should be fully involved in planning adaptation measures.

New ecosystem-based solutions which provide flexible resilience to coastal flooding, rather than rigid defences, are needed in the face of global environmental change. A recent study examines a new coastal protection scheme in the Netherlands which reduces ecosystem damage whilst offering resilient defence against flooding. Using this case study, the researchers present a framework for evaluating climate change adaptation measures called ‘Building with Nature’.

Denmark aims to develop an energy system based only on renewable energy sources by 2050. Energy saving buildings are an essential part of this plan, according to new research, which investigates how excess heat production from net zero energy buildings (NZEBs) can benefit district heating systems and reduce reliance on combustible fuels.

Implementing energy efficiency measures in existing housing stock could save 10% of current heating consumption by 2020 and 20% by 2030, according to a recent study of nine European countries. Planning authorities can play a major role by providing support and unbiased information to all stakeholders involved in the renovations.

Climate change may increase the risk of outbreaks of infectious diseases, such as salmonella or tick-borne encephalitis. A new study has outlined five main steps in assessing policies to ensure that they can respond effectively to this challenge and highlights the importance of involving stakeholders at every stage of policy assessment.

Over half of a low-energy building’s environmental impact occurred before it was even occupied, a new case study from Italy calculates. The researchers recommend expanding the environmental assessment of buildings from just the operational stage of a building’s life, when it is in use, to include production and transport of materials, construction activities and building maintenance. A wide range of environmental impacts should also be considered, they argue, and not just energy use.

Spanish medical and public health researchers have found no clear evidence for increased heavy metal levels in adults living near a recently-built urban solid waste incinerator over two years of operation. Concentrations of lead, chromium and mercury in blood and urine samples taken around the plant were not significantly higher than for populations who lived further away.

A recent study has examined how ships no longer economical to run are broken apart, reassembled and made into goods of new value, such as furniture, in Bangladesh. There are strong concerns about working conditions for those who work in this industry and ship breaking yards have recently been closed as they are considered hazardous. However, this study draws a valuable lesson from ship breaking in that 'things are but temporary configurations of material', which can, potentially, be endlessly reassembled, under safe conditions.

Flat screen televisions and computer monitors should be designed so they can be quickly dismantled for recycling, a recent study says. The researchers calculated that in order to ensure the recycling process remains economically viable, it must be possible to disassemble small screens in less than 11 minutes. Good design could lower the costs of recycling and enable near-total recovery of precious metals from the waste screens.

Food packaging waste is currently under scrutiny. In the context of its Circular Economy Action Plan, the EU is addressing this through, among others, its Product Environmental Footprint (PEF) initiative , which aims to enhance the reliability of environmental claims — both in a business-to-consumer and in a business-to-business context. The initiative aims, therefore, to boost the market of green and circular products. However, a review of the methods available for assessing the environmental sustainability of packaging now highlights the difficulty of clearly characterising packaging's environmental impact. The study suggests a new, fully quantifiable framework that could help to standardise assessment methods and bring 'environmental footprint labelling' to fruition.